United StatesA study published in The Lancet Infectious Diseases found that Pfizer's Paxlovid, an antiviral medication used to treat acute COVID-19, did not provide clinical benefits for individuals suffering from long COVID. The research, conducted by investigators at Boston's Mass General Brigham health system and funded by the National Institutes of Health, tested Paxlovid and its components against a placebo over 15 to 25 days. Researchers observed that the drug did not demonstrate effectiveness in addressing persistent viral activity associated with long-term symptoms. This finding contrasts with Paxlovid's established efficacy in treating acute infections. The article also includes unrelated news about drug pricing deals and new guidelines for migraine prevention.
Bias read (Center): While the study itself is a scientific report, the broader context involves pharmaceutical policies and healthcare administration, which are politically charged topics. However, the article presents the findings objectively without overtly favoring any political ideology. The framing remains neutral
